The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

References

• Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM 2006;99:1–14
   PubMed Web of Science ®Google Scholar
• Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97–104
   PubMed Web of Science ®Google Scholar
• Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43: 1363–79
   PubMed Web of Science ®Google Scholar
• Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525–32
   PubMed Web of Science ®Google Scholar
• Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7: 53–72
   PubMed Web of Science ®Google Scholar
• El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;49:547–53
   PubMed Web of Science ®Google Scholar
• Bjornheden T, Babyi A, Bondjers G, et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996;123:43–56
   PubMed Web of Science ®Google Scholar
• Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998;39:1263–73
   PubMed Web of Science ®Google Scholar
• Camejo G, Lopez A, Lopez F, et al. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 1985;55:93–105
   PubMed Web of Science ®Google Scholar
• Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001;110:103–10
   PubMed Web of Science ®Google Scholar
• de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298–306
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143–421
   Google Scholar
• Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 2006;20:205–17
   PubMed Web of Science ®Google Scholar
• Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25:199–211
   Google Scholar
• Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992;95:35–42
   Google Scholar
• Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584–92
   PubMed Web of Science ®Google Scholar
• Zhao SP, Smelt AH, Leuven JA, et al. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. Am J Med 1994;96:49–56
   PubMed Web of Science ®Google Scholar
• Bredie SJ, de Bruin TW, Demacker PN, et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipo-protein oxidizability. Am J Cardiol 1995;75:348–53
   PubMed Web of Science ®Google Scholar
• Franceschini G, Lovati MR, Manzoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995;114:61–71
   PubMed Web of Science ®Google Scholar
• Nestel P, Simons L, Barter P, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997;129:231–9
   PubMed Web of Science ®Google Scholar
• O’Neal DN, O’Brien RC, Timmins KL, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med 1998;15:870–7
   PubMed Web of Science ®Google Scholar
• Wagner AM, Jorba O, Bonet R, et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003;88:3212–7
   PubMed Web of Science ®Google Scholar
• Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol 2005;96:1266–72
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556–63
   PubMed Web of Science ®Google Scholar
• Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1–11
   Google Scholar
• Yoshida H, Ishikawa T, Ayaori M, et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 1998;139:179–87
   PubMed Web of Science ®Google Scholar
• Nakandakare E, Garcia RC, Rocha JC, et al. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis 1990;85:211–7
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA, Zambon A, et al. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:427–34
   PubMedGoogle Scholar
• Dachet C, Cavallero E, Martin C, et al. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis 1995;113:1–9
   PubMed Web of Science ®Google Scholar
• Yang CY, Gu ZW, Xie YH, et al. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyper-lipidemia. Atherosclerosis 1996;126:105–16
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37–45
   PubMed Web of Science ®Google Scholar
• Homma Y, Ozawa H, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994;106:191–201
   PubMed Web of Science ®Google Scholar
• Hayashi K, Kurushima H, Kuga Y, et al. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. Cardiovasc Drugs Ther 1998;12:3–12
   PubMed Web of Science ®Google Scholar
• Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipo-protein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648–56
   PubMed Web of Science ®Google Scholar
• Toyota Y, Yamamura T, Miyake Y, et al. Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis 1999;147:77–86
   PubMed Web of Science ®Google Scholar
• Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59:181–9
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Noma K, Tohyama J, et al. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia – a nuclear magnetic resonance study. Int J Cardiol 2005;101:441–7
   PubMed Web of Science ®Google Scholar
• Ayaori M, Momiyama Y, Fayad ZA, et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 2006 Dec 29; [Epub ahead of print]
   Google Scholar
• Kondo A, Morita H, Nakamura H, et al. Influence of fibrate treatment on malondialdehyde-modified LDL concentration. Clin Chim Acta 2004;339:97–103
   PubMed Web of Science ®Google Scholar
• Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395–9
   PubMed Web of Science ®Google Scholar
• Deighan CJ, Caslake MJ, McConnell M, et al. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol 2001;12:341–8
   PubMed Web of Science ®Google Scholar
• Frost RJ, Otto C, Geiss HC, et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein sub-fraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44–8
   PubMed Web of Science ®Google Scholar
• Tan CE, Chew LS, Tai ES, et al. Benefits of micronised fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 2001;154:469–74
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002;144:E6
   PubMedGoogle Scholar
• Lemieux I, Laperriere L, Dzavik V, et al. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002;162:363–71
   PubMed Web of Science ®Google Scholar
• Lemieux I, Salomon H, Despres JP. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann Med 2003;35: 442–8
   Google Scholar
• Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733–7
   PubMed Web of Science ®Google Scholar
• Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956–60
   PubMed Web of Science ®Google Scholar
• Badiou S, Merle De Boever C, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273–9
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278–85
   PubMedGoogle Scholar
• Winkler K, Weltzien P, Friedrich I, et al. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes 2004;112:241–7
   PubMed Web of Science ®Google Scholar
• Ruel IL, Lamarche B, Mauger JF, et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arterioscler Thromb Vasc Biol 2005;25:2600–7
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2006 Aug 12; [Epub ahead of print]
   Google Scholar
• Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyper-lipidemia. Arterioscler Thromb Vasc Biol 1996;16:763–72
   PubMed Web of Science ®Google Scholar
• Davidson MH, Bays HE, Stein E, et al. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol 2006;29:268–73
   PubMed Web of Science ®Google Scholar
• Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91–102
   Google Scholar
• Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7:843–50
   PubMed Web of Science ®Google Scholar
• Raslova K, Nagyova A, Dobiasova M, et al. Effect of ciprofibrate on lipoprotein metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype. Acta Diabetol 2000;37:131–4
   PubMed Web of Science ®Google Scholar
• Guerin M, Le Goff W, Frisdal E, et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipo-protein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003;88:3738–46
   PubMed Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269–76
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44:927–34
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264–73
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227–39
   Google Scholar
• Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: 1849–61
   Google Scholar
• Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199–207
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravaststin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349–57
   Google Scholar
• Downs JR, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1625–6
   Web of Science ®Google Scholar
• Rizzo M, Berneis K. Effects of statins on low-density-lipoproteins size: a new role in cardiovascular prevention? South Med J 2006;99:1015–16
   PubMedGoogle Scholar
• Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137–43
   PubMed Web of Science ®Google Scholar
• Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of efficacy and safety. Eur Heart J 1995;16:5–13
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin + fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;40:265–71
   Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155–68
   PubMed Web of Science ®Google Scholar
• Farnier M, Freeman MW, Macdonell G, et al.; the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897–905
   Google Scholar
• Hanak V, Munoz J, Teague J, et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol 2004;94:219–22
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399–404
   PubMed Web of Science ®Google Scholar